Although the underlying mechanism of E2F1-mediated MYCN downregulation during oncolytic virotherapy remains unclear, our data suggest that hTERT-driven oncolytic adenoviruses are promising antitumor reagents for eliminating MYCN-amplified NB cells via E2F1-mediated MYCN downregulation. The gene discussed is MYCN; the disease is neuroblastoma.